Selected article for: "hepatitis virus and virus detection"
Author: Baha Abdalhamid; Christopher R Bilder; Emily L McCutchen; Steven H Hinrichs; Scott A Koepsell; Peter C Iwen
Title: Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources
  • Document date: 2020_4_6
    • ID: fmbowr9g_12
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https: //doi.org/10.1101 //doi.org/10. /2020 Since the first detection in Wuhan, China in December 2019, severe acute respiratory 43 syndrome coronavirus 2 (SARS-CoV-2), the pathogen of coronavirus diseases 2019 , 44 has spread worldwide to now be considered a pandemic 1, 2 swabs. The second step in the assay employs reverse transcription and amplification using a real .....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https: //doi.org/10.1101 //doi.org/10. /2020 Since the first detection in Wuhan, China in December 2019, severe acute respiratory 43 syndrome coronavirus 2 (SARS-CoV-2), the pathogen of coronavirus diseases 2019 , 44 has spread worldwide to now be considered a pandemic 1, 2 swabs. The second step in the assay employs reverse transcription and amplification using a real 54 time PCR instrumentation. The assay therefore requires two kits, one for extraction and another 55 for amplification of the target and detection. We investigated whether a strategy used in the testing 56 of blood prior to transfusion could have application for conservation of scarce reagents for the 57 SARS CoV-2 assay 4,5 . The process of group testing that employs sample pooling is used for 58 detection of the human immunodeficiency virus, and hepatitis B and C viruses 4 in blood products.

    Search related documents:
    Co phrase search for related documents
    • detection target amplification and human immunodeficiency virus: 1
    • group testing and sample pooling: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • group testing and SARS assay: 1, 2, 3, 4, 5, 6, 7, 8
    • group testing and testing strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • group testing and worldwide spread: 1
    • human immunodeficiency and SARS assay: 1, 2, 3, 4, 5, 6, 7
    • human immunodeficiency and second step: 1
    • human immunodeficiency and testing strategy: 1, 2, 3, 4
    • human immunodeficiency and worldwide spread: 1, 2, 3
    • human immunodeficiency virus and SARS assay: 1, 2, 3, 4, 5, 6, 7
    • human immunodeficiency virus and second step: 1
    • human immunodeficiency virus and testing strategy: 1, 2, 3, 4
    • human immunodeficiency virus and worldwide spread: 1, 2, 3
    • sample pooling and SARS assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • sample pooling and testing strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • SARS assay and testing strategy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • SARS assay and worldwide spread: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • second step and testing strategy: 1, 2, 3
    • testing strategy and worldwide spread: 1, 2, 3, 4